

1671



RECEIVED

SEP 19 2001

TECH CENTER 1600/2901

AMENDMENT TRANSMITTAL LETTER			DOCKET NUMBER: P-PM 4097	
SERIAL NO: 09/575,061	FILING DATE: 05/19/2000	EXAMINER: G. Gabel	GROUP ART U 1641	
INVENTION: DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE USING THE OmpC ANTIGEN				

TO COMMISSIONER FOR PATENTS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on September 14, 2001.

By: Andrea L. Gashler  
Andrea L. Gashler, Reg. No. 41,029

September 14, 2001  
Date of Signature

Transmitted herewith is a Response to Restriction Requirement in connection with the above-identified application.

- \_\_\_ Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- \_\_\_ Petition for Extension of Time is enclosed (in duplicate).
- x No additional claims fee is required.
- \_\_\_ An additional claims fee is required and has been calculated as shown below:

## CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE			FEE	
							SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	13	-	20	-	0	x	\$9	\$18	=	\$0	\$
INDEPENDENT CLAIMS	4	-	4	-	0	x	\$40	\$80	=	\$0	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			___ YES		___ x NO		\$135	\$270	=	\$0	\$
							TOTAL ADDITIONAL FEE			\$0	\$

\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

\*\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\* If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.

\_\_\_ Please charge my Deposit Account No. 03-0370 the amount of \$ \_\_\_\_\_. A duplicate copy of this sheet is enclosed.

\_\_\_ A check in the amount of \$ \_\_\_\_\_ is enclosed, \$ \_\_\_\_\_ of which covers the fee for a \_\_\_\_\_ -month extension of time.


Inventors: Targan et al.  
Serial No.: 09/575,061  
Filed: May 19, 2000  
Page 2 of 2

- X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- X Any additional filing fees required under 37 C.F.R. 1.16.
- X Any patent application processing fees under 37 C.F.R. 1.17.
- X The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

September 14, 2001  
Date

Andrea L. Gashler  
Andrea L. Gashler  
Registration No. 41,029  
CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive  
7<sup>th</sup> Floor  
San Diego, California 92122  
858-535-9001  
**USPTO CUSTOMER NO. 23601**



PATENT  
Our Docket: P-LJ 4097

#9  
PI?  
9/19/07

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Targan et al.

Serial No.: 09/575,061

Filed: May 19, 2000

For: DIAGNOSIS, PREVENTION AND  
TREATMENT OF CROHN'S  
DISEASE USING THE OmpC  
ANTIGEN

)  
) Examiner: G. Gabel  
)

) Group Art Unit: 1641  
)

) I hereby certify that this correspondence  
) is being deposited with the United States  
) Postal Service as first class mail in an  
) envelope addressed to: Commissioner for  
) Patents, Washington, D.C., 20231, on  
) September 14, 2001.

) By Andrea L. Gashler  
) Andrea L. Gashler, Reg. No. 41,029

Commissioner for Patents  
Washington, D.C. 20231

September 14, 2001  
Date of Signature

**RESPONSE TO RESTRICTION REQUIREMENT**

Responsive to the Office Action mailed August 28, 2001,  
consideration of the following remarks respectfully is requested.

**I. REMARKS**

Claims 1 to 13 are pending. The Examiner alleges that  
the claims are directed to two distinct and independent  
inventions as follows:

Group I: Claims 1 to 11, drawn to methods of  
diagnosing Crohn's disease; and

Group II: Claims 12 and 13, drawn to methods of  
inducing tolerance in a patient with  
Crohn's disease.